[go: up one dir, main page]

WO1999053945A8 - Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone - Google Patents

Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone

Info

Publication number
WO1999053945A8
WO1999053945A8 PCT/CA1999/000304 CA9900304W WO9953945A8 WO 1999053945 A8 WO1999053945 A8 WO 1999053945A8 CA 9900304 W CA9900304 W CA 9900304W WO 9953945 A8 WO9953945 A8 WO 9953945A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
growth inhibitory
axon regeneration
derivatives
neuron growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000304
Other languages
English (en)
Other versions
WO1999053945A1 (fr
Inventor
Samuel David
Lisa Joan Mckerracher
Peter Erich Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU31347/99A priority Critical patent/AU3134799A/en
Publication of WO1999053945A1 publication Critical patent/WO1999053945A1/fr
Publication of WO1999053945A8 publication Critical patent/WO1999053945A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions comprenant des agents immunogènes possédant des propriétés d'inhibition de croissance de neurones, ces compositions entraînant la génération d'anticorps polyréactifs se liant à des inhibiteurs de croissance de l'axone, ce qui favorise la régénération de l'axone. Ces agents comprennent de la glycoprotéine associée à la myéline (MAG), ainsi que des protéines arrétine ou protéoglycane. On peut utiliser ces compositions pour restaurer des transmissions nerveuses, notamment une fonction motrice et sensorielle après des lésions de la moelle épinière ou des lésions du nerf optique. On peut également les utiliser pour traiter des affections impliquant des lésions de l'axone telles qu'une sclérose en plaques et un accident vasculaire cérébral. On peut enfin utiliser les compositions selon l'invention comme vaccins prophylactiques avant que ne survienne une maladie ou une lésion du système nerveux central.
PCT/CA1999/000304 1998-04-16 1999-04-16 Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone Ceased WO1999053945A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU31347/99A AU3134799A (en) 1998-04-16 1999-04-16 Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,234,921 1998-04-16
CA2234921 1998-04-16

Publications (2)

Publication Number Publication Date
WO1999053945A1 WO1999053945A1 (fr) 1999-10-28
WO1999053945A8 true WO1999053945A8 (fr) 2000-03-02

Family

ID=4162334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000304 Ceased WO1999053945A1 (fr) 1998-04-16 1999-04-16 Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone

Country Status (2)

Country Link
AU (1) AU3134799A (fr)
WO (1) WO1999053945A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
NZ541694A (en) 2000-01-12 2006-08-31 Univ Yale Nogo receptor-mediated blockade of axonal growth
AUPQ614200A0 (en) * 2000-03-10 2000-03-30 Department Of Human Physiology, Flinders University School Of Medicine Method for treating chronic spinal cord injury
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2007014075A2 (fr) 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Modulation par l'arni du gene rho-a dans des modeles de recherche

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191326535A (en) * 1913-11-19 1914-04-23 Charles Jules Henri Nicolle Improvements in and relating to Vaccines, Cultures and the like and the Preparation thereof.
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
AU6858596A (en) * 1995-08-25 1997-03-19 Johns Hopkins University School Of Medicine, The Compounds for stimulating nerve growth
CA2190418A1 (fr) * 1996-11-15 1998-05-15 Zhi-Cheng Xiao Systeme regulateur pour la croissance des neurones et des tumeurs neuronales; anticorps utilises a cette fin et applications

Also Published As

Publication number Publication date
WO1999053945A1 (fr) 1999-10-28
AU3134799A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
TW264480B (fr)
WO2003053336A3 (fr) Procedes de traitement de malaises neurovasculaires peripheriques
WO1998026747A3 (fr) Procedes et compositions de traitement de maladies a base de superantigenes
WO1996004378A3 (fr) Proteines chimeriques et muteines des inhibiteurs des voies du facteur tissulaire de la coagulation tfpi et tfpi-2
WO2002029059A3 (fr) Homologues du recepteur de nogo
WO2004087203A3 (fr) Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
WO2001001748A3 (fr) Composés se liant à her2
WO2005055944A3 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
WO2003057134A8 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
WO2003030934A3 (fr) Formulations cpg et procedes y relatifs
WO2003016467A3 (fr) Utilisation d'anticorps ayant une forte affinite pour le peptide a$g(b) dans le traitement de pathologies et de maladies liees a a$g(b)
WO1999041383A8 (fr) Immunisation par bibliotheque d'antigenes
ATE441663T1 (de) Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
WO2004110360A3 (fr) Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
WO2001060347A3 (fr) Methode de traitement des douleurs oculaires
EP1195161A3 (fr) Anti-IgE vaccins
WO2005002526A3 (fr) Procedes et compositions pour le traitement d'infections virales
WO1998014596A3 (fr) Tyrosine phosphatases proteiques associees a des maladies
WO2002018620A3 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO1999053945A8 (fr) Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone
WO2003033658A3 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO2002036614A3 (fr) Peptides destines a une utilisation dans le traitement de la maladie d'alzheimer
WO2003001968A8 (fr) Compositions et procedes prohibant l'activation plaquettaire et la thrombose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B8

Designated state(s): AE

AL Designated countries for regional patents

Kind code of ref document: B8

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 43/99 UNDER (54) THE TITLE IN ENGLISH SHOULD READ "NEURON GROWTH INHIBITORY MOLECULES OR DERIVATIVES THEREOF USED TO IMMUNIZE MAMMALS THEREBY PROMOTING AXON REGENERATION"

NENP Non-entry into the national phase in:

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

122 Ep: pct application non-entry in european phase